Core Viewpoint - ProMIS Neurosciences, Inc. is actively participating in the Guggenheim Emerging Outlook: Biotech Summit 2026, highlighting its focus on developing next-generation therapies for Alzheimer's disease and other neurodegenerative disorders [1] Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company dedicated to discovering and developing therapeutic antibodies and vaccines that target toxic oligomers associated with neurodegenerative diseases [3] - The company utilizes its proprietary EpiSelect™ target discovery engine to identify Disease Specific Epitopes (DSEs) on misfolded proteins linked to diseases such as Alzheimer's, ALS, FTD, MSA, and PD [3] Product Development - PMN310 is the lead product candidate designed as a humanized monoclonal antibody that selectively targets toxic oligomers while avoiding plaque, potentially reducing amyloid-related imaging abnormalities (ARIA) [4] - PMN310 received Fast Track designation from the U.S. FDA in July 2025, indicating its potential for expedited development [4] Clinical Trials - Following positive results from the Phase 1a trial, ProMIS initiated the PRECISE-AD Phase 1b clinical trial to evaluate the safety, tolerability, and pharmacokinetics of PMN310 in patients with Mild Cognitive Impairment and mild Alzheimer's disease [5] - The PRECISE-AD trial is designed as a randomized, double-blind, placebo-controlled study with multiple ascending doses (5, 10, 20 mg/kg) and aims to assess the effects of PMN310 on biomarkers and clinical outcomes associated with Alzheimer's disease [5] EpiSelect Drug Discovery Engine - The EpiSelect platform enables the identification of conformational epitopes on toxic misfolded proteins, facilitating the development of selective therapeutic antibodies and vaccines [6] - PMN310 has shown high selectivity for toxic amyloid-beta oligomers without significant reactivity with other forms, potentially minimizing risks associated with targeting vascular or parenchymal amyloid [6]

Group 1 - The article emphasizes the importance of understanding key trends and catalysts in the biotech, pharma, and healthcare industries to make informed investment decisions [1] - Edmund Ingham, a biotech consultant, has extensive experience covering over 1,000 companies in the biotech, healthcare, and pharma sectors [1] - The Haggerston BioHealth investing group provides insights for both novice and experienced investors, including product sales forecasts and integrated financial statements [1]

Core Insights - The company reported a 3% revenue growth in local currencies for the first half of 2025/26, but a 1% decline in Danish kroner to DKK 249.0 million year-on-year, primarily due to a slowdown in US demand caused by a government shutdown [1][6] - Despite the challenges, EBITDA increased by 1% to DKK 136.2 million, resulting in an EBITDA margin of 55%, up from 54% in the previous year [6] Revenue Performance - Revenue in Q2 2025/26 decreased by 8% to DKK 124.4 million compared to DKK 135.9 million in the same period last year [5][6] - Sales of instruments fell by 12% to DKK 77.0 million in the first half, while sales of consumables and services increased by 6% and 3%, respectively, accounting for 45% and 23% of total revenue [6] Product Performance - Sales of the XcytoMatic instruments experienced a significant organic growth of 60% year-on-year, reaching DKK 30.8 million, despite the overall decline in instrument sales [1][6] - Positive customer feedback on new products highlights their precision, user-friendliness, and integration into automated workflows, indicating strong potential for future growth [4] Market Outlook - The US cell and gene therapy market is identified as an area of potential growth, driven by significant investments from major players [2] - The company is focusing on establishing new partnerships, particularly with European firms in the bioprocessing segment, to enhance workflow automation solutions [3] Financial Guidance - The company maintains its full-year revenue guidance for 2025/26 in the range of DKK 565-580 million and EBITDA guidance in the range of DKK 320-335 million [7]

Core Viewpoint - Transgene, a biotech company specializing in virus-based immunotherapies for cancer treatment, has announced its financial reporting and annual shareholders' meeting dates for 2026 [1]. Financial Reporting Schedule - The company will release its 2025 Fiscal Year Results on March 24, 2026 [1]. - The First Quarter 2026 Financial Results will be announced on April 29, 2026 [1]. - The Annual Shareholders' Meeting is scheduled for May 13, 2026 [1]. - The First Half 2026 Financial Results will be disclosed on September 24, 2026 [1]. - The Third Quarter 2026 Financial Results will be reported on November 9, 2026 [1]. Company Overview - Transgene focuses on designing and developing targeted immunotherapies for cancer, with a portfolio of viral vector-based immunotherapeutics [2]. - The lead asset, TG4050, is the first individualized therapeutic vaccine based on the myvac® platform, showing proof of principle in treating head and neck cancers [2]. - Other assets include BT-001, an oncolytic virus in clinical development, and ongoing innovative discovery and preclinical work for novel immunotherapies [2]. Technological Innovation - The myvac® platform enables precision medicine through a tailored virus-based immunotherapy that incorporates patient-specific mutations identified by Artificial Intelligence in collaboration with NEC [3].

Amgen Stock Hits Buy Zone On Positive 2026 Outlook Amid Sharpening Obesity Focus | Investor's Business DailyBREAKING: [Eli Lilly Surges As Obesity Drugs Fuel Strong Earnings, Guidance]---Amgen (AMGN) stock popped Wednesday — surging back into a buy zone — on its surprisingly upbeat 2026 guidance despite biosimilar competition for bone health drugs Prolia and Xgeva. Prolia is an osteoporosis treatment. Xgeva aims to prevent fractures and spinal cord compression in patients who have bone metastases from cance ...

Core Insights - Bio-Techne Corporation (TECH) reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 46 cents, exceeding the Zacks Consensus Estimate by 8.2% and reflecting a year-over-year increase of 9.5% [1] - The company's net sales for the quarter were $295.9 million, showing a slight decline of 0.4% year over year, but surpassing the Zacks Consensus Estimate by 1.3% [2] - The operating profit for the quarter was $54.5 million, an increase from $47.4 million in the prior year, with the operating margin expanding by 244 basis points to 18.4% [6][8] Revenue Breakdown - In the Protein Sciences segment, Bio-Techne recorded revenues of $215.1 million, a 2% increase year over year, although it was down 1% on an organic basis [3] - The Diagnostics and Spatial Biology segment saw a revenue decrease of 4% year over year to $81.2 million, but it increased by 3% on an organic basis [4] Margin Analysis - Gross profit fell by 1.3% to $191.3 million, with the gross margin contracting by 63 basis points to 64.6% due to a 1.4% rise in the cost of sales [5] - Selling, general and administrative expenses decreased by 6.4% to $113.7 million, while research and development expenses totaled $23.1 million, down 7.6% year over year [5] Financial Position - At the end of the fiscal second quarter, Bio-Techne had cash and equivalents of $172.9 million, up from $145 million at the end of the previous quarter, while long-term debt obligations decreased to $260 million from $300 million [7] Overall Performance - Despite a quarterly revenue decline and gross margin contraction, there are signs of stabilization in the U.S. academic market, improving performance in biotech, ongoing growth in Asia, and continued strength among large pharmaceutical customers [10]

Financial Data and Key Metrics Changes - Adjusted EPS for Q2 was $0.46, up 10% year-over-year, while GAAP EPS increased to $0.24 from $0.22 in the prior year [19] - Total revenue for Q2 was $295.9 million, flat year-over-year on both an organic and reported basis, with foreign currency exchange contributing a 2% tailwind [19][20] - Adjusted gross margin was 68.5%, down from 70.5% last year, driven by unfavorable product and customer mix [21] - Adjusted operating margin reached 31.1%, up 100 basis points year-over-year, reflecting productivity gains and cost management [21][22] Business Line Data and Key Metrics Changes - Protein Sciences segment reported sales of $215.1 million, an increase of 2% year-over-year, but organic revenue declined 1% [23] - Diagnostics and spatial biology segment sales were $81.2 million, down 4% year-over-year, with organic growth of 3% after accounting for divestitures [25] - Core reagents and assays, proteomic analysis instruments, and diagnostic kits all saw modest growth in Q2 compared to Q1 [5][6] Market Data and Key Metrics Changes - Revenue from large pharma customers increased low double digits for the fourth consecutive quarter, while emerging biotech declined mid-single digits [9] - U.S. academic business experienced a modest decline, partially offset by stable growth in Europe, resulting in a low single-digit decline overall for this end market [10] - China grew mid-single digits, marking its third consecutive quarter of growth, supported by R&D investments from CDMO, CRO, and biotech customers [10] Company Strategy and Development Direction - The company focuses on four strategically important growth verticals: cell therapy, proteomic analytical instrumentation, spatial biology, and precision diagnostic tools, which now represent 47% of total revenue [7] - The company is committed to maintaining a strong profitability profile while investing in strategic growth initiatives [6][18] - The upcoming fiscal year 2027 is expected to see normalization in growth as headwinds from key customers dissipate [26][66] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stabilization of end markets, particularly in biotech funding and U.S. academic budgets, which are expected to improve gradually [18][60] - The company anticipates that the headwinds from FDA Fast Track designations for key customers will moderate, allowing for improved growth in the future [26][66] - Management highlighted the importance of AI as a driver for demand in biotech, suggesting it will enhance productivity and specificity in R&D [44][45] Other Important Information - The company is actively pursuing M&A opportunities to enhance its portfolio, particularly in novel antibodies and cell therapy [80] - The acquisition of Wilson Wolf is on track, with expectations to complete it by the end of calendar year 2027 [13][81] - The company launched Cultrex Synthetic Hydrogel to support organoid development, aligning with trends towards reduced use of animal models [78] Q&A Session Summary Question: Growth cadence and expectations for fiscal year 2026 - Management confirmed expectations for mid-single-digit growth in Q4, primarily driven by normalization from key customers and continued strength in pharma [30][32] Question: Drivers of gross margin changes - Management indicated that unfavorable product mix and customer profiles impacted gross margins, but improvements are expected in the latter half of the year [34][36] Question: Impact of AI on biotech demand - Management believes AI will enhance customer capabilities and drive demand for more complex materials, benefiting the company [44][45] Question: Biotech funding and timing of revenue impact - Management noted a typical six-month lag for funding improvements to translate into revenue, with positive trends observed in funding activity [61][62] Question: Cell therapy customer impact on GMP business - Management expects normalization in the GMP business as headwinds from key customers dissipate, with underlying growth previously observed at 30% [65][66]

Financial Data and Key Metrics Changes - Adjusted EPS for Q2 was $0.46, up 10% year-over-year, with GAAP EPS at $0.24, up from $0.22 in the prior year [19][20] - Total revenue for Q2 was $295.9 million, flat year-over-year on both an organic and reported basis, with foreign currency exchange contributing a 2% tailwind [20][22] - Adjusted gross margin was 68.5%, down from 70.5% last year, while adjusted operating margin reached 31.1%, up 100 basis points year-over-year [22][24] Business Line Data and Key Metrics Changes - Protein Sciences segment reported sales of $215.1 million, with organic revenue declining 1%, but excluding cell therapy timing impacts, organic growth was 4% [24][25] - Diagnostics and spatial biology segment sales were $81.2 million, down 4% year-over-year, with 3% organic growth after accounting for divestiture impacts [26] - Core reagent and assay portfolio delivered low double-digit growth for the quarter, while proteomic analytical tools grew upper single digits [15][25] Market Data and Key Metrics Changes - Revenue from large pharma customers increased low double digits for the fourth consecutive quarter, while emerging biotech declined mid-single digits [9][21] - U.S. academic business saw a modest decline, partially offset by stable growth in Europe, resulting in a low single-digit decline overall for this end market [10][21] - China grew mid-single digits, marking its third consecutive quarter of growth, supported by R&D investments from CDMO, CRO, and biotech customers [10][21] Company Strategy and Development Direction - Company focuses on four strategically important growth verticals: cell therapy, proteomic analytical instrumentation, spatial biology, and precision diagnostic tools, which now represent 47% of total revenue [6][19] - The company aims to balance growth investments with operational efficiency, targeting 100 basis points of operating margin expansion for the full fiscal year [29] - Continued emphasis on innovation and product introductions to drive growth in key markets, particularly in organoids and multiomics [80][84] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stabilization of end markets, particularly in biotech funding and U.S. academic budgets, which are expected to improve gradually [18][27] - The company anticipates that the headwinds from FDA Fast Track designations for two major customers will moderate, allowing for a return to normalized growth [27][68] - Overall sentiment remains positive regarding the company's competitive position and the potential for growth in the upcoming fiscal year [19][68] Other Important Information - The company is actively pursuing M&A opportunities to enhance its portfolio, particularly in novel antibodies and cell therapy [84] - The acquisition of Wilson Wolf is on track, with expectations to complete it by the end of calendar year 2027 [12][84] - The company launched Cultrex Synthetic Hydrogel to support organoid development, aligning with trends towards reducing animal model usage [80] Q&A Session Summary Question: Growth cadence and expectations for fiscal year 2026 - Management confirmed expectations for mid-single-digit growth in fiscal year 2026, excluding specific customer impacts [31][32] Question: Drivers of gross margin changes - Management explained that gross margin decline was due to unfavorable product mix and customer profiles, with expectations for gradual improvement [34][36] Question: Impact of AI on biotech demand - Management believes AI will enhance customer capabilities and drive demand for more complex materials, benefiting the company [44][45] Question: Biotech funding and timing of revenue impact - Management indicated a typical 6-month lag for funding improvements to reflect in revenue, with positive trends observed in funding and M&A activity [62][63] Question: Cell therapy customer impacts on GMP business - Management noted that the two major customers' Fast Track designations have created temporary headwinds, but growth is expected to normalize post-2027 [66][68]

Vancouver, British Columbia – TheNewswire - February 4, 2026 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), (the “Company” or “MindBio”), is pleased to report following its recent success in meeting with mining and health executives in South America, it has deployed a team of software engineers to the mining industry in country. The team deployed will be working with health and mining officials to build a protocol for practical implementation of drug and alcohol screening by voice. ...

Core Viewpoint - Polyrizon Ltd. has signed a non-binding Memorandum of Understanding (MOU) to acquire a 51% stake in Arrow Aviation, a high-growth private aviation company, for approximately $5.8 million, marking a strategic entry into the private aviation sector [1][3]. Company Overview - Polyrizon is a pre-clinical-stage biotechnology company focused on developing intranasal protective solutions, including innovative medical device hydrogels delivered as nasal sprays [5]. - Arrow Aviation is a leading provider of private aviation services with annual unaudited revenues of approximately $19 million and adjusted EBITDA of around $3 million, operating a fleet of executive jets and offering tailored VIP flights [2]. Strategic Expansion - The acquisition of Arrow Aviation is seen as a diversification opportunity for Polyrizon, allowing the company to leverage its financial position to enter a private aviation market projected to grow to $41.38 billion by 2030 [3]. - The proposed transaction includes arrangements for a Hawker 800 aircraft valued at $3.5 million and the forgiveness of outstanding shareholder debts by existing Arrow Aviation shareholders in exchange for convertible notes from Polyrizon [3]. Transaction Timeline - A definitive agreement is expected to be signed within 30 days of the MOU, subject to due diligence, with the closing of the acquisition anticipated to follow customary closing conditions [4].